The p-value of the SMR association for CTC-228N24.3 was similar to that of SLC12A2. However, the posterior probability for a common variant between CTC-228N24.3 and overall BC risk was 77%, less than that for SLC12A2 (81.5%). This evidence concerns the gene SLC12A2 and breast cancer.